European Journal of Medical Research - Deutsche AIDS ...

June 27, 2007 EUROPEAN JOURNAL OF MEDICAL RESEARCH
83
D.11 (Poster)
Virological medical quality management -
7 year follow-up of HIV treatment
Knechten H. 1 , Höhn C. 1 , Ehret R. 1 , Wiesmann F. 1 ,
Braun P. 1
1 PZB Aachen, Aachen, Germany
Purpose: The HIV treatment guidelines have been modified recently
and recommend that a viral load 1 diarrhea per day prior to switching vs. 32.8 % of pts after
switching. 40.3 % of pts used antidiarrheal medication before
switching vs. 30.3 % of those afterwards.
Overall Quality of Life improved in 27 % and deteriorated
in 10 % of pts. 29 % of pts experienced fewer loose stools and
11 % reported more. 29 % of pts reported less diarrhea and 6
% reported more. In 20 % of pts use of antidiarrheal medication
was reduced vs. 2 % of pts in which the use increased.
75.4 % of pts preferred LPV/r TAB therapy, 2.7 % preferred
therapy with LPV/r SGC and 20.3 % judged both therapies
equal (1.5 % n. a.).
Conclusion: In this unselected group of patients a trend to
improved Quality of Life and reduced GI side effects is observed
after switch from LPV/r SGC to LPV/r TAB.
D.13 (Vortrag)
Long-term efficacy of Enfurvitide – final results of
the RADATA-Fuzeon cohort
Hoffmann C. 1 , Lorenzen T. 1 , Bogner J.R. 2 , van Lunzen J. 3 ,
Staszewski S. 4 , Arbter P. 5 , Faetkenheuer G. 6 , Gute P. 7 ,
Stoll M. 8 , Hintsche B. 9 , Walther I. 1 , Waesle B. 10 ,
Stoehr A. 1 , Plettenberg A. 1
1 ifi-Institut für interdisziplinäre Medizin, Hamburg, Germany,
2 Medizinische Poliklinik, Klinikum der Universität München
Innenstadt, Infektionsambulanz, München, Germany,
3 Universitätsklinikum Hamburg-Eppendorf,
Ambulanzzentrum Infektiologie, Hamburg, Germany,
4 Universität Frankfurt, HIV-Center, Frankfurt, Germany,
5 Praxis für Allgemeinmedizin, Krefeld, Germany, 6 Klinikum
der Universität zu Köln, Klinik I für Innere Medizin, Köln,
Germany, 7 HIV-Schwerpunktpraxis, Frankfurt, Germany,
8 Medizinische Hochschule Hannover, Abteilung Klinische
Immunologie, Hannover, Germany, 9 Praxis für Innere
Medizin, Berlin, Germany, 10 Roche-Pharma AG, Grenzach-
Wyhlen, Germany
Background: Data on long-term efficacy of enfuvirtide outside
clinical trials is limited. In the Radata-Fuzeon cohort,
data of HIV-1-infected patients (pts) treated with enfuvirtide
in clinical practice were collected from 32 German centers.
The setting offered planning of background therapy according
to resistance analysis, adherence questionnaire, therapeutic
drug monitoring and external expert advice.
Methods: All pts in whom a switch to a new enfuvirtidebased
antiretroviral therapy (ART) was intended were included
in this prospective cohort study. Clinical, immunological
and virological outcomes were measured every three months.
Results: Of 233 pts included, 173 received enfuvirtide and
were eligible for analysis. Pts were heavily pretreated at baseline
(median time on ART: 80 months, number of prior regimens:
10), showing a median of 7 (range, 1-18) and 2 (range,
1-4) resistance mutations in the reverse transcriptase and in
the protease gene locus, respectively. Pts had a median viral